Stock Market Reviews

TARS (Tarsus Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on TARS (Tarsus Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
  IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tar
  Oct 28, 2025 - $TARS
• Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
  Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Oct 9, 2025 - $TARS
• Why Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's Next
  In recent days, Tarsus Pharmaceuticals has attracted increased investor attention following the strong uptake of its prescription eye drop Xdemvy, which treats Demodex blepharitis, and the announcement of preparations for mid-stage clinical trials targeting ocular rosacea and Lyme disease. This surge in interest highlights how the rapid commercial adoption of Xdemvy and an expanding development pipeline can shape future business prospects for the company. We’ll explore how robust demand for...
  Oct 8, 2025 - $TARS
• Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
  Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Oct 6, 2025 - $TARS
• Tarsus to Participate in Upcoming Investor Conferences
  IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th Annual Healthcare Conference on Wednesday, September 3rd, at 6:30 a.m. PT / 9:30 a.m. ETH.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of t
  Aug 27, 2025 - $TARS
• This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine
  Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points.
  Aug 15, 2025 - $TARS
• Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.
  This biotech is nearing a buy point of a cup base. The company has a treatment for Lyme disease in its pipeline.
  Aug 14, 2025 - $TARS
• Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report
  NasdaqGS:TARS 1 Year Share Price vs Fair Value Explore Tarsus Pharmaceuticals's Fair Values from the Community and...
  Aug 9, 2025 - $TARS
• Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
  Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions Pipeline advancements and global efforts remain on track Management to host conference call today, August 6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals
  Aug 6, 2025 - $TARS
• Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
  Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $TARS